Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Employees - 1,
CEO - Dr. Garo H. Armen Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 4.05M
Altman ZScore(max is 10): -70.17, Piotroski Score(max is 10): 3, Working Capital: $-148803, Total Assets: $988650, Retained Earnings: $-37743221, EBIT: -5260443, Total Liabilities: $1076979, Revenue: $0
AryaFin Target Price - $0.37 - Current Price $6.88 - Analyst Target Price $-
| Ticker | PTIX |
| Index | - |
| Curent Price | 6.88 |
| Change | -38.02% |
| Market Cap | 4.05M |
| Average Volume | 2.02M |
| Income | -5.24M |
| Sales | 0.00M |
| Book Value/Share | -0.16 |
| Cash/Share | 1.48 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 3 |
| Moving Avg 20days | 84.01% |
| Moving Avg 50days | 82.83% |
| Moving Avg 200days | 2.90% |
| Shares Outstanding | 0.54M |
| Earnings Date | - |
| Inst. Ownership | 7.01% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | - |
| Price/Cash | 4.66 |
| Price/FCF | - |
| Quick Ratio | 0.86 |
| Current Ratio | 0.86 |
| Debt/Equity | - |
| Return on Assets | -293.85% |
| Return on Equity | -512.79% |
| Return on Investment | - |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 59.96 |
| BETA(β) | - |
| From 52week Low | 192.77% |
| From 52week High | -73.72% |
| EPS | -13.14 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | -10.56% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 31.66% |
| Sales Y/Y | - |
| EPS Q/Q | 49.43% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 1.58 |
| Perf Week | 96.01% |
| Perf Month | 135.13% |
| Perf Quarter | 94.24% |
| Perf Year | -64.63% |
| Perf YTD | 0.29% |
| Target Price | - |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer